19,800 new cases of hepatitis B infection (HBV) occur annually in the United States resulting in approximately 1.4 million cases of chronic infection. Is your practice ready?


  • Review current HBV screening guidelines
  • Solutions to patient and clinic barriers to screening
  • The basics of serology and etiology in HBV
  • Current, near term and in-development new treatments for HBV


A 26 year old male presents for his first visit to your practice. He does not have a vaccination record. He was born in the US to immigrants from Turkey. Should you screen for HBV?

Which of the following is an appropriate method to address HBV screening concerns:

According to the US Preventive Task Force recommendations, patients born in the following regions should be screened EXCEPT those from:

Which of the following is NOT true about tenofovir alafenamide (TAF)?

How confident are you in your ability to identify and overcome patient barriers to screening for HBV?

How confident are you in your ability to explain how current therapies interact with the HBV life cycle to disrupt viral replication?

How confident are you in your ability to discuss recent treatment guidelines and supporting clinical data to manage HBV infection?